Executives from CVS Health and Aetna sought to assure lawmakers that their US$69 billion merger would create value for consumers and not result in anti-competitive behavior. They spoke at a hearing before the House Judiciary Regulatory Reform, Commercial and Antitrust Law Subcommittee on Tuesday, February 27.
Despite raising concerns that the deal would be bad for consumers and the healthcare system, the AMA’s statement did not ask Congress or regulators to block the deal.
Full Content: Medpage Today
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Glencore and Rio Tinto in Talks Over Deal That Could Create $260 Billion Mining Giant
Jan 8, 2026 by
CPI
Google, Meta, Amazon, Microsoft, Netflix Set to Avoid Tough EU Curbs: Report
Jan 8, 2026 by
CPI
EU Antitrust Review of Google-Wiz Deal Draws Intense Scrutiny Ahead of 2026 Deadline
Jan 8, 2026 by
CPI
Bankers Renew Their Plea to Close ‘Loophole’ in Stablecoin Law’s Ban on Interest Payments
Jan 8, 2026 by
CPI
M&A Rebound Lifts Elite Law Firms After Near-Record Deal Year
Jan 8, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 16, 2025 by
CPI
Learning from Divergence: The Role of Cross-Country Comparisons in the Evaluation of the DMA
Dec 16, 2025 by
Federico Bruni
New Regulatory Tools for the EU Foreign Direct Investment Screening and Foreign Subsidies Regulation
Dec 16, 2025 by
Ioannis Kokkoris
“Suite Dreams”: Market Definition and Complementarity in the Digital Age
Dec 16, 2025 by
Romain Bizet & Matteo Foschi
The Interaction Between Competition Policy and Consumer Protection: Institutional Design, Behavioral Insights, and Emerging Challenges in Digital Markets
Dec 16, 2025 by
Alessandra Tonazzi